Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: Which is more appropriate terminology?

Annals of Oncology

Volumn 27, Issue 8, 2016, Pages 1650-1651

  Paydas, S ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; PEMBROLIZUMAB; MONOCLONAL ANTIBODY;

CANCER GROWTH; CASE REPORT; CELL DIFFERENTIATION; CLINICAL PRACTICE; DISEASE SEVERITY; HUMAN; LETTER; LUNG BIOPSY; LUNG SARCOIDOSIS; LYMPH NODE BIOPSY; NOMENCLATURE; PRIORITY JOURNAL; IMMUNOLOGY; IMMUNOTHERAPY;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOTHERAPY; SARCOIDOSIS, PULMONARY;

EID: 84984949415     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw193     Document Type: Letter

References (7)

1. Cousin A, Toulmonde M, Kind M et al. Pulmonary sarcoidosis induced by the anti- PD-1 monoclonal antibody pembrolizumab. Ann Oncol 2016; 27: 1178-1179.
2. Judson AM, Morgenthau AS, Baughman RP. Murray and Nadel's textbook of Respiratory Medicine, Chapter 66. 2015; 1188-1206.
3. Paydas S, Yavuz S, Disel U et al. Granulomatous reaction after chemotherapy for Hodgkin's disease. Leuk Res 2002; 26: 967-970.
4. Daly PA, O'Brian DS, Robinson I, Guckian M, Prichard JS. Hodgkin's disease with a granulomatous pulmonary presentation mimicking sarcoidosis. Thorax 1988; 43: 407-409.
5. Wilgenhof S, Morlion V, Seghers AC et al. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res 2012; 32(4): 1355-1359.
6. Vogel WV, Guislain A, Kvistborg P et al. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol 2012; 30: e7-e10.
7. Berthod G, Lazor R, Letovanec I et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 2012; 30: 156-159.